EcoDrugPlus

Matrix Metallopeptidase 1

Ensembl ID : ENSAOCG00000010251
Gene Symbol: MMP1
4 Cross references
307 Possible Orthologues:

Matrix Metallopeptidase 2

Ensembl ID : ENSAOCG00000007186
Gene Symbol: MMP2
3 Cross references
210 Possible Orthologues:

Matrix Metallopeptidase 9

Ensembl ID : ENSAOCG00000016707
Gene Symbol: MMP9
3 Cross references
216 Possible Orthologues:

Matrix Metalloproteinase-14-Like

Ensembl ID : ENSAOCG00000016552
Gene Symbol: LOC111577984
3 Cross references
198 Possible Orthologues:

Matrix Metalloproteinase-14-Like

Ensembl ID : ENSAOCG00000021597
Gene Symbol: LOC111587803
3 Cross references
199 Possible Orthologues:

Mechanistic Target Of Rapamycin Kinase

Ensembl ID : ENSAOCG00000023912
Gene Symbol: MTOR
3 Cross references
222 Possible Orthologues:

Melanocortin 1 Receptor

Ensembl ID : ENSAOCG00000004549
Gene Symbol: MC1R
3 Cross references
159 Possible Orthologues:

Melanocortin 4 Receptor

Ensembl ID : ENSAOCG00000022631
Gene Symbol: MC4R
1 Cross references
211 Possible Orthologues:

Melanoma Receptor Tyrosine-Protein Kinase-Like

Ensembl ID : ENSAOCG00000020243
Gene Symbol: LOC111586710
2 Cross references
212 Possible Orthologues:

Melatonin Receptor 1a

Ensembl ID : ENSAOCG00000014587
Gene Symbol: MTNR1A
3 Cross references
190 Possible Orthologues:

Membrane Metalloendopeptidase

Ensembl ID : ENSAOCG00000018642
Gene Symbol: MME
4 Cross references
234 Possible Orthologues:

Metabotropic Glutamate Receptor 2-Like

Ensembl ID : ENSAOCG00000002888
Gene Symbol: LOC111574940
3 Cross references
210 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).